CN113134085A - 一种治疗外阴白色病变的药物 - Google Patents

一种治疗外阴白色病变的药物 Download PDF

Info

Publication number
CN113134085A
CN113134085A CN202010051825.1A CN202010051825A CN113134085A CN 113134085 A CN113134085 A CN 113134085A CN 202010051825 A CN202010051825 A CN 202010051825A CN 113134085 A CN113134085 A CN 113134085A
Authority
CN
China
Prior art keywords
vulva
medicine
vitamin
treating
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202010051825.1A
Other languages
English (en)
Inventor
张伶俐
黄蕊
韩璐
林芸竹
杨春松
黄红
付雨之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
West China Second University Hospital of Sichuan University
Original Assignee
West China Second University Hospital of Sichuan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West China Second University Hospital of Sichuan University filed Critical West China Second University Hospital of Sichuan University
Priority to CN202010051825.1A priority Critical patent/CN113134085A/zh
Publication of CN113134085A publication Critical patent/CN113134085A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明公开了一种治疗外阴白色病变的药物，该药物包括以下组分：性激素、糖皮质激素、外用麻醉药、复合维生素和润肤剂混合。该药物可有效解决现有的药物存在的复发率高、治疗效果差以及无法根治的问题。

Description

一种治疗外阴白色病变的药物
技术领域
本发明涉及医学技术领域，具体涉及一种治疗外阴白色病变的药物。
背景技术
外阴白色病变，是一种女性外阴皮肤及黏膜发生组织变化和色素改变的妇科慢性疾病，过去因临床和病理认识不同，曾称外阴干枯症、外阴白斑或外阴营养不良等，属于外阴上皮内非瘤样病变。主要症状为外阴奇痒、外阴皮肤粘膜发白、粗糙、增厚、弹性减退、甚至造成阴道口狭窄、性交疼痛等，其病程长，复发率高，瘙痒剧烈程度不分季节与昼夜，给患者带来了极大痛苦和不便。
此外，外阴白色病变的确切病因不明，可能与遗传基因、自身免疫、性激素缺乏或性激素受体下降等因素有关。现有医疗技术在治疗外阴白色病变时，主要有以下几种方式：
1、糖皮质激素
应用糖皮质激素的目的在于控制局部瘙痒、抗炎及抗过敏作用，抑制结缔组织细胞增生，还可稳定细胞内溶酶体膜，防止细胞内溶酶体酶释放组织而引起组织损伤。临床常用的药物有0.01％曲安奈德软膏或0.025％氟轻松软膏或 1-2％氢化可的松软膏。一般认为糖皮质激素治疗鳞状上皮增生的效果优于硬化性苔藓，临床上外阴白色病变进行药物治疗时多用糖皮质激素。
2、性激素
丙酸睾酮属于雄性激素类药物，具有促进蛋白合成的作用，能促使萎缩的皮肤恢复正常或接近正常皮肤厚度，临床一般用丙酸睾酮涂擦，或将丙酸睾酮配以维生素B2、鱼肝油或加凡士林制成油剂。青春期前硬化苔藓患者以长期使用丙酸睾酮引起男性化患者，可以采用黄体酮100mg加入30g凡士林油膏局部涂擦以代替丙酸睾酮。
3、激光治疗
一般采用CO2激光或氦氖激光治疗，破坏达2mm皮肤层，消灭异常上皮组织和破坏真皮层内神经末梢，从而阻断瘙痒和搔抓所引起的恶性循环。
4、冷冻治疗
冷冻治疗可以调节外阴病变组织的免疫反应，提高局部组织免疫能力及修复创伤组织的能力，起到止痒痛和治愈外阴白色病变的作用。一般均采用液氮进行治疗，虽然其近期效果好，但远期复发率较高。
5、超声治疗
超声治疗是近年发展的一种微创技术，超声治疗可以使真皮内组织包括血管和神经末梢发生变性，继而促进该处新的微血管形成和改进神经末梢的营养状况以达到治疗的目的。
6、手术治疗
手术治疗仅适用于1)局部病损组织出现不典型增生或恶变可能；2)反复应用药物治疗或物理治疗无效，因病灶局限，可考虑单纯性病灶切除。病变范围及广，多需性单纯外阴切除术。为避免术后瘢痕形成和阴道口狭窄引起性交痛，有学者主张在术时做皮片移植。外阴切除术后患者症状迅速消失，但远期复发率仍高达39-50％，且术后仍有长期随访的必要。
7、中药治疗
中医上普遍采用在内治基础上配合外治法，内治以辨证分型施治为主，外治以杀虫止痒为主，佐以祛风除湿、清热解毒、活血化瘀等药局部外洗、外搽；简便易行，患者的依从性较好，但仍存在着不足之处，如疗程长、治愈率低及易复发、远期效果差等问题。
由于外阴白色病变的发病机制不明确，上述现有治疗方法都是从缓解患者的不适症状入手，即使通过手术等方法去除了病灶，但复发率高于50％，反复发作为患者带来巨大痛苦，导致目前该病没有确切的治疗方法。
发明内容
针对现有技术中的上述不足，本发明提供了一种治疗外阴白色病变的药物，该药物可有效解决现有的药物存在的复发率高、治疗效果差以及无法根治的问题。
为实现上述目的，本发明解决其技术问题所采用的技术方案是：
一种治疗外阴白色病变的药物，该药物包括以下组分：
性激素、糖皮质激素、外用麻醉药、复合维生素和润肤剂。
进一步地，性激素为丙酸睾酮、苯酸睾酮、黄体酮或己烯雌酚。
进一步地，糖皮质激素为曲安奈德、氢化可的松、倍他米松、氯倍他索、氟轻松或地塞米松。
进一步地，外用麻醉药为达克罗宁、丁卡因或利多卡因。
进一步地，维生素为维生素A、维生素B族、维生素D和维生素E中的一种或多种。
进一步地，润肤剂为白凡士林、甘油、鱼肝油、椰子油、月桂醇和辛酸辛酯中的一种或多种。
本发明所产生的有益效果为：本发明中的药物具有见效快、治疗费用低、治疗操作方便的优点。本发明中通过性激素药物和维生素类药物为患者的外阴局部皮肤补充营养，糖皮质激素可控制局部瘙痒，具有抗炎及抗过敏的作用，通过外用麻醉药抑制触觉和痛觉，实现止痛，止痒的作用，以上药物联合使用，达到标本兼治的目的。
具体实施方式
实施例1
一种治疗外阴白色病变的药物，包括以下组分：
丙酸睾酮、曲安奈德、达克罗宁、白凡士林和维生素B族按照 0.1:0.003:0.3:30:0.1的质量比混合，制成外涂混合物。
实施例2
一种治疗外阴白色病变的药物，包括以下组分：
黄体酮、氢化可的松、丁卡因、鱼肝油和维生素E按照0.2:0.6:0.3:30:0.2的质量比混合，制成外涂混合物。
对比例1
一种治疗外阴白色病变的药物，包括以下组分：
苯酸睾酮、丁卡因、鱼肝油和维生素E按照0.1:0.3:30:0.2的质量比混合，制成外涂混合物。
对比例2
一种治疗外阴白色病变的药物，包括以下组分：
苯酸睾酮、氢化可的松、鱼肝油和维生素E按照0.1:0.6:30:0.2的质量比混合，制成外涂混合物。
对比例3
一种治疗外阴白色病变的药物，包括以下组分：
氢化可的松、丁卡因、鱼肝油和维生素E按照0.6:0.3:30:0.2的质量比混合，制成外涂混合物。
试验例
随机寻找25位患有外阴白色病变的患者，分成5组，每组5人，分别使用实施例1-2和对比例1-3中的方法为他们进行治疗，治疗1个月、2个月和3个月后，观察并记录患者的病情，具体见表1-3。
疗效标准：治愈：自觉症状消失，外阴颜色、弹性基本恢复正常；
显效：自觉症状消失、局部皮肤变光泽、柔软、粉红；
好转：自觉症状消失，局部皮肤变光泽，但颜色无改变；
无效：病变处无明显变化或进一步加重。
表1：1月后疗效表
例数(例) 治愈 显效 好转 无效 治愈率(％) 有效率(％)
实施例1 5 0 2 3 0 0 100
实施例2 5 0 1 4 0 0 100
对比例1 5 0 0 1 4 0 20
对比例2 5 0 0 2 3 0 40
对比例3 5 0 0 1 4 0 20
通过上表得知，按照本发明实施例1-2中的治疗方法治疗1个月以后，患者的症状出现好转，有效率均达到100％，而按照对比例1-3中的治疗方法治疗1 个月后，病情出现好转的人数较少，有效率最高仅为40％。
表2：2月后疗效表
例数(例) 治愈 显效 好转 无效 治愈率(％) 有效率(％)
实施例1 5 1 2 2 0 20 100
实施例2 5 1 2 2 0 20 100
对比例1 5 0 1 1 3 0 40
对比例2 5 0 1 0 4 0 20
对比例3 5 0 0 1 4 0 20
通过上表得知，按照本发明实施例1-2中的治疗方法治疗2个月以后，患者的症状出现好转，有效率均达到100％，而按照对比例1-3中的治疗方法治疗2 个月后，病情出现好转的人数较少，有效率最高仅为40％。
表3：3月后疗效表
例数(例) 治愈 显效 好转 无效 治愈率(％) 有效率(％)
实施例1 5 3 2 0 0 60 100
实施例2 5 3 1 1 0 60 100
对比例1 5 0 2 1 2 0 60
对比例2 5 0 1 2 2 0 60
对比例3 5 0 0 1 4 0 20
通过上表得知，本发明实施例1-2中的治疗方法对于外阴白色病变具有很好的治疗效果，其治愈率高达60％，有效率高达100％，而按照对比例1-3中的治疗方法治疗3个月后，病情出现显效的人数较少，有效率最高仅为60％，实施例1-2中的治疗方法远远高于对比例1-3中的治疗方法。

Claims (6)

1.一种治疗外阴白色病变的药物，其特征在于，该药物包括以下组分：
性激素、糖皮质激素、外用麻醉药、复合维生素和润肤剂。
2.如权利要求1所述的治疗外阴白色病变的药物，其特征在于，所述性激素为丙酸睾酮、苯酸睾酮、黄体酮或己烯雌酚。
3.如权利要求1所述的治疗外阴白色病变的药物，其特征在于，所述糖皮质激素为曲安奈德、氢化可的松、倍他米松、氯倍他索、氟轻松或地塞米松。
4.如权利要求1所述的治疗外阴白色病变的药物，其特征在于，所述外用麻醉药为达克罗宁、丁卡因或利多卡因。
5.如权利要求1所述的治疗外阴白色病变的药物，其特征在于，所述维生素为维生素A、维生素B族、维生素D和维生素E中的一种或多种。
6.如权利要求1所述的治疗外阴白色病变的药物，其特征在于，所述润肤剂为白凡士林、甘油、鱼肝油、椰子油、月桂醇和辛酸辛酯中的一种或多种。
CN202010051825.1A 2020-01-17 2020-01-17 一种治疗外阴白色病变的药物 Withdrawn CN113134085A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010051825.1A CN113134085A (zh) 2020-01-17 2020-01-17 一种治疗外阴白色病变的药物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010051825.1A CN113134085A (zh) 2020-01-17 2020-01-17 一种治疗外阴白色病变的药物

Publications (1)

Publication Number Publication Date
CN113134085A true CN113134085A (zh) 2021-07-20

Family

ID=76809603

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010051825.1A Withdrawn CN113134085A (zh) 2020-01-17 2020-01-17 一种治疗外阴白色病变的药物

Country Status (1)

Country Link
CN (1) CN113134085A (zh)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1425403A (zh) * 2002-12-27 2003-06-25 陈利馨 一种治疗外阴白色病变的软膏及其制备方法
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
CN1660130A (zh) * 2004-12-20 2005-08-31 凌沛学 含海藻糖和透明质酸的人体润滑剂及其制备方法
CN1738599A (zh) * 2001-08-16 2006-02-22 艾克塞斯制药公司 控制药物与其它活性化合物给药的粘膜粘着性可侵蚀药物递送器具
CN1965864A (zh) * 2006-11-24 2007-05-23 首都医科大学附属北京妇产医院 一种治疗外阴白色病变的药物组合物、制剂及其制备方法
US20100183723A1 (en) * 2004-09-15 2010-07-22 Neocutis S.A. Fetal Skin Cell Protein Compositions for the Treatment of Skin Conditions, Disorders or Diseases and Methods of Making and Using the Same
CN102281870A (zh) * 2008-12-10 2011-12-14 安徽中人科技有限责任公司 新型控释组合物
CN102688259A (zh) * 2011-03-23 2012-09-26 李霖 一种治疗外阴上皮内非瘤样病变的清白止痒膏
CN108704020A (zh) * 2018-08-03 2018-10-26 李淑玲 一种治疗外阴白色病变的药物及其制备方法

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1738599A (zh) * 2001-08-16 2006-02-22 艾克塞斯制药公司 控制药物与其它活性化合物给药的粘膜粘着性可侵蚀药物递送器具
CN1425403A (zh) * 2002-12-27 2003-06-25 陈利馨 一种治疗外阴白色病变的软膏及其制备方法
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20100183723A1 (en) * 2004-09-15 2010-07-22 Neocutis S.A. Fetal Skin Cell Protein Compositions for the Treatment of Skin Conditions, Disorders or Diseases and Methods of Making and Using the Same
CN1660130A (zh) * 2004-12-20 2005-08-31 凌沛学 含海藻糖和透明质酸的人体润滑剂及其制备方法
CN1965864A (zh) * 2006-11-24 2007-05-23 首都医科大学附属北京妇产医院 一种治疗外阴白色病变的药物组合物、制剂及其制备方法
CN102281870A (zh) * 2008-12-10 2011-12-14 安徽中人科技有限责任公司 新型控释组合物
CN102688259A (zh) * 2011-03-23 2012-09-26 李霖 一种治疗外阴上皮内非瘤样病变的清白止痒膏
CN108704020A (zh) * 2018-08-03 2018-10-26 李淑玲 一种治疗外阴白色病变的药物及其制备方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
东敏，等: "外阴白色病变西医治疗研究进展", 《医学信息》 *
李世文，等: "《当代妇产科妙方》", 31 August 2008, 人民军医出版社 *
李昶亮，等: "《健康与长寿知识问题》", 31 July 1989 *
王桂珍，等: "女阴白色病损", 《黑龙江医药》 *
附二院妇产科教研室: "外阴白斑", 《武汉医学院学报》 *

Similar Documents

Publication Publication Date Title
JP7198785B2 (ja) ペプチドの抗炎症的使用
US20130052273A1 (en) Pharmaceutical composition comprising periplaneta americana or its ethanol extract and a method of using the same for treating inflammations
JP2020527134A (ja) モンテルカストおよびイガイ接着タンパク質との組み合わせを含む局所製剤
Renzi et al. Pneumatic balloon dilatation for chronic anal fissure: a prospective, clinical, endosonographic, and manometric study
RU2221561C2 (ru) Витамин е и его сложные эфиры для местного лечения патологий слизистой оболочки
KR20140127296A (ko) 조성물 및 항문 균열 치료에서의 그 용도
WO2020143744A1 (en) New formulations containing leukotriene receptor antagonists
CN113134085A (zh) 一种治疗外阴白色病变的药物
WO2017129108A1 (zh) 一种用于治疗皮肤病的硅凝胶
WO2018072731A1 (en) Wound healing composition
CN107596370A (zh) 一种治疗宫颈糜烂的药物复方制剂及用途
Julio et al. Radiofrequency treatment of labial hemangioma
CN110433284A (zh) 一种治疗宫颈炎的组合物、凝胶剂及其制备方法
CN104490870A (zh) 一种复方局部用乳膏及其应用
Zhao et al. Effect of local oxygen therapy combined with vacuum sealing drainage on the healing of stage IV sacrococcygeal pressure ulcers
RU2810361C1 (ru) Способ лечения офтальморозацеа по точкам
RU2814360C1 (ru) Способ лечения фиматозного подтипа розацеа по точкам
RU2811254C1 (ru) Способ лечения эритемато-телеангиоэктатического подтипа розацеа по точкам
RU2814362C1 (ru) Способ лечения розацеа с солидным персистирующим отёком по точкам
RU2810400C1 (ru) Способ лечения стероидной розацеа по точкам
CA2219226A1 (en) Irritation relief using nonsteroidal anti-inflammatory compounds
RU2814358C1 (ru) Способ лечения папуло-пустулёзного подтипа розацеа по точкам
US20080194471A1 (en) Compositions and Methods for Treating Wounds
Mbanefo et al. MP47-11 DOWNREGULATION OF PRO-INFLAMMATORY PATHWAYS BY IPSE, A UROGENITAL PARASITE-DERIVED IMMUNOMODULATORY PROTEIN, REDUCES IFOSFAMIDE-INDUCED HEMORRHAGIC CYSTITIS
Shaheed et al. Evaluation of Botulonium Toxin Type A in the Management of Keloid Scar

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20210720

WW01 Invention patent application withdrawn after publication